TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$175 Million

Novavax, Inc.

Bookrunner, December 2022

Novavax, Inc.
Senior Convertible Notes Offering

Novavax, Inc. (NVAX) (“Novavax”) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. Novavax has developed a COVID-19 vaccine (“NVX-CoV2373”), and is developing an influenza vaccine candidate, a COVID-19-Influenza Combination vaccine candidate, and additional vaccine candidates, including for Omicron subvariants, and bivalent formulations with prototype vaccine (NVX-CoV2373). NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

More Like This

Mar 2024

Exchange of all Outstanding Series B Convertible Preferred Stock for Common Stock

Financial Advisor

View Details >
Mar 2024
$600 Million

Follow-on Offering

Bookrunner

View Details >
Mar 2024
$150 Million

Underwritten Offering

Lead Left Bookrunner

View Details >